A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Subscribe To Our Newsletter & Stay Updated
